Search


Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces
He shares an update on the ulixacaltamide and relutrigine filings, and how he thinks about potential commercialization opportunities. Plus, late stage readouts to watch out for. Coverage brought to you by
51 minutes ago


BIO 2026: With two CNS programs in front of FDA and a third that has received breakthrough therapy designation, Praxis Precision Medicines isn't taking its success for granted or slowing down
CEO Marcio Souza walks us through essential tremor and the mechanism of ulixacaltamide, and also comments on a recent seizure trial that did not succeed. Plus, preparing for potential commercial launches and how he thinks about M&A. Coverage brought to you by
Jun 23


The CEO of Praxis Precision Medicines discusses the company's CNS focus and key data that is scheduled for this year
Marcio Souza describes Praxis' small molecule and antisense oligonucleotide platforms, and previews key trials that will have near term data
Aug 14, 2024






.png)
